GC Green Cross Wellbeing Reports 101.2 Billion Won in First-Half Sales, Up 37.4% Year-on-Year

Operating profit up 2.6% to 9.5 billion won year-on-year

Flagship placenta injection "Laennec" drives performance

GC Green Cross Wellbeing announced on July 31 that its consolidated sales for the first half of this year reached 101.2 billion won, a 37.4% increase compared to the same period last year. Operating profit was 9.5 billion won, up 2.6% from a year earlier.

GC Green Cross Wellbeing Company Logo Image. GC Green Cross Wellbeing

The company's performance was driven by its flagship placenta injection product, "Laennec." Laennec's first-half sales totaled 25.5 billion won, representing an increase of approximately 26% compared to 20.3 billion won during the same period last year. The company explained that profitability improved alongside a rise in capacity utilization rates and a reduction in cost ratio, thanks to expanded production.

Laennec recently met the primary endpoint in a Phase 3 clinical trial for high-dose intravenous administration. The company plans to apply for product approval from the Ministry of Food and Drug Safety within the year.

Although marketing expenses increased due to investments in "Giselle," a skin booster, and "Rivonne," a filler launched during the first half of the year in the aesthetics business, the company expects sales related to these products to be fully reflected starting in the second half.

Consolidated subsidiary Honestree posted sales of 9.6 billion won for the first half, marking a 50% increase compared to the same period last year.

This content was produced with the assistance of AI translation services.